Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (3)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Pickering, W. P.
Right arrow Articles by Bevington, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pickering, W. P.
Right arrow Articles by Bevington, A.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nephrol Dial Transplant (2003) 18: 1475-1484
© 2003 European Renal Association-European Dialysis and Transplant Association

Glucocorticoid antagonist RU38486 fails to block acid-induced muscle wasting in vivo or in vitro

Warren P. Pickering, Frease E. Baker, Jeremy Brown, Heather L. Butler, Sheena Govindji, Julie M. Parsons, Izabella Z. A. Pawluczyk, John Walls{dagger} and Alan Bevington

Department of Nephrology, Leicester General Hospital, Leicester, UK

Correspondence and offprint requests to: Alan Bevington, Department of Nephrology, Leicester General Hospital, Gwendolen Road, Leicester LE5 4PW, UK. Email: ab74{at}leicester.ac.uk

Background. Increased protein degradation during metabolic acidosis contributes to muscle wasting in uraemia. Adrenalectomy experiments in severely acidotic rats (arterial pH ~7.15) have shown that this is prevented in the absence of glucocorticoid. It should therefore be possible to block such muscle wasting with glucocorticoid receptor antagonist 11ß-(4-dimethylaminophenyl)-17ß-hydroxy,-17a-(prop-1-ynyl)-estra-4,9-dien-3-one (RU38486).

Methods. The effect of oral RU38486 (50 mg/kg body weight/day) was studied in vivo by administration to rats receiving dietary HCl supplements which yielded moderate acidosis (plasma HCO3 19.7 ± 1.2 mmol/l), comparable with that observed in uraemia. The effect of the glucocorticoid dexamethasone (DEX) (up to 500 nmol/l) and RU38486 (up to 5 µmol/l) was also studied in vitro in acidified cultures of L6-G8C5 rat skeletal muscle cells.

Results. In vivo 15 days of moderate acidosis slowed weight gain and induced muscle wasting (6% weight loss in gastrocnemius with a commensurate decline in muscle protein) but, at this level of acidosis, muscle protein degradation showed no detectable increase. Wasting was not inhibited by RU38486 in spite of blockade of 80% of the glucocorticoid receptors in gastrocnemius. Unexpectedly, weight gain was significantly slower in acidotic rats receiving RU38486 than in acidotic rats receiving vehicle. In vitro acid spontaneously stimulated protein degradation, but even under strongly acidic conditions (pH 7.1) this was only weakly and transiently stimulated by 5 nmol/l DEX and transiently blunted by 5 µmol/l RU38486. In contrast, as little as 1 nmol/l insulin-like growth factor I (IGF-I) almost abolished the effect of acid and this was partly restored by 5 nmol/l DEX.

Conclusions. IGF-I is a potent determinant of acid-induced protein degradation in vitro and is antagonized by glucocorticoid. If glucocorticoid acts in this indirect way in vivo this may explain why, in moderate metabolic acidosis with intact adrenal glands, the action of RU38486 via glucocorticoid is too weak to be of therapeutic value.

Keywords: glucocorticoid; insulin-like growth factor I; metabolic acidosis; protein degradation; RU38486; skeletal muscle

{dagger}Deceased.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Nephrol Dial TransplantHome page
D. Teta, A. Tedjani, M. Burnier, A. Bevington, J. Brown, and K. Harris
Glucose-containing peritoneal dialysis fluids regulate leptin secretion from 3T3-L1 adipocytes
Nephrol. Dial. Transplant., July 1, 2005; 20(7): 1329 - 1335.
[Abstract] [Full Text] [PDF]



Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.